• MitoCareX Bio, a wholly owned Nexentis unit, moved its computational drug-discovery infrastructure to Google Cloud Platform.
• Shift targets scalable computing for research programs, tighter scientific data governance, controlled access, improved workflow continuity.
• Deployment centralizes data management, standardizes user permissions, supports flexible storage and compute as project needs change.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070732PRIMZONEFULLFEED9841289) on October 07, 2026, and is solely responsible for the information contained therein.